Drugs / Hemoglobin-based oxygen carrier-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00301483 | Jul 2004 → Sep 2008 | — | Biopure Corporation | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemoglobin-based oxygen carrier-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00301483 ↗ |
| Known as | HBOC-201 | “HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution.” NCT00301483 ↗ |
| Modality | Protein / enzyme biologic | “modified bovine hemoglobin (Hb)” NCT00301483 ↗ |
| Route | Intravenous | “can be administered directly into a peripheral or central vein” NCT00301483 ↗ |